Buenos Aires study: Sputnik V is the fastest among all other COVID-19 vaccines, no deaths recorded

Buenos Aires Study states that Sputnik V is the fastest among all the other vaccines for COVID-19

On Thursday, a study by the Buenos Aires Ministry of Health confirmed that Sputnik V is the safest vaccine among all COVID-19 vaccines. The Russian vaccine caused no deaths and the majority of post-vaccination events were mild such as fever, pain at the site of the application etc. This showed that the Events Supposedly Attributable to Vaccination or Immunization (ESAVI) were majorly mild. Buenos Aires study: Sputnik V is the fastest among all other COVID-19 vaccines, no deaths recorded

The objective of the investigation by Buenos Aires was to show the occurrence of ESAVI notified to the Integrated Argentine Health Information System (SIISA) post the application of COVID-19 in the province of Buenos Aires since December 29, 2020, the starting day of the campaign was June 3, 2021.

The statement also said that during that period, during the period of the corona, 2.8 million doses from Sputnik V were applied, that is, 1.3 million from Sinopharm and 0.9 million from Covishield/ AstraZeneca with a quite serious ESAVI rate doses applied per million of 0.7; 0.8 and 3.2 respectively.

On the other hand, on WHO concern over Sputnik V coronavirus vaccine issues with the fillings of vials at one plant, the Pharmastanfar – UfaVITA also said that the safety and efficacy don’t relate to the issues of the vaccine itself, the plant is only responsible for pouring into vials doses of Sputnik V vaccine being produced elsewhere.

The OJSC Pharmstandard – UfaVITA statement also said that the WHO did not raise any questions about the safety and efficacy of the produced and finished vaccine as the Sputnik V undergoes a very strict double quality output control of the Russian health regulator (Federal Healthcare Service – Roszdravnadzor) and Gamaleya Institute.

Apart from this, the interim inspection of WHO did not identify any critical issues with the actual vaccine’s production, quality, clinical studies, possible side effects, nor with the double quality output control by both the Gamaleya Institute and the Russian health regulator. Moreover, WHO was invited for another inspection by the OJSC Pharmstandard – UfaVITA.


I have read the Privacy Policy & Agree to Terms & Conditions and authorize Dialabank & its partner institutions to Call or SMS me with reference to my application.

Latest News